Five-year data for EssilorLuxottica’s Stellest lens showed an average reduction in children’s myopia progression by 1.75D and 0.72mm in axial elongation over five years. 

The five-year data demonstrate conclusive evidence of the Stellest lens’ efficacy in slowing down myopia progression in children in the fifth year and that the effect was sustained in older children (up to 18 years old), said the company.  

Initially presented at the Association for Research in Vision and Ophthalmology earlier this year, the controlled, prospective, randomised clinical trial was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. The age of the children was eight to 13 years old at enrolment in 2018.  

Originally extended from a two- to a five-year clinical trial to assess long-term efficacy, EssilorLuxottica said it plans to extend it for a further two years.